Quarterly report pursuant to Section 13 or 15(d)

TSO - Additional Information (Detail)

v2.4.0.8
TSO - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended 84 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 22, 2013
Jun. 30, 2013
USD ($)
Jun. 30, 2012
USD ($)
Jun. 30, 2013
USD ($)
Jun. 30, 2012
USD ($)
Jun. 30, 2013
USD ($)
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
USD ($)
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
EUR (€)
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
Minimum [Member]
Feb. 22, 2013
Joint Ownership and Exclusive License Agreement Fu Berlin [Member]
Maximum [Member]
Feb. 22, 2013
License and Sublicense Agreement with Ovamed GmbH [Member]
Minimum [Member]
Feb. 22, 2013
License and Sublicense Agreement with Ovamed GmbH [Member]
Maximum [Member]
Feb. 22, 2013
License and Sublicense Agreement with Ovamed GmbH [Member]
Letter Agreement [Member]
USD ($)
Feb. 22, 2013
License and Sublicense Agreement with Ovamed GmbH [Member]
Letter Agreement [Member]
EUR (€)
Feb. 22, 2013
Research and Development Arrangement [Member]
USD ($)
Feb. 22, 2013
Research and Development Arrangement [Member]
EUR (€)
Jun. 30, 2013
Research and Development Arrangement [Member]
USD ($)
Jun. 30, 2013
Research and Development Arrangement [Member]
USD ($)
Long-term Purchase Commitment [Line Items]                                    
Expected project duration under research agreement                             4 years 4 years    
Research and development expense   $ 7,795,000 $ 4,525,000 $ 13,769,000 $ 9,116,000 $ 55,778,000                 $ 853,000 € 648,000 $ 52,700 $ 75,000
Written notice period under research agreement termination                             3 months 3 months    
Potential milestone payments based primarily on the achievement of clinical development and regulatory milestones             4,982,000 3,830,000                    
Percentage of royalty on net sales of products range                 1.00% 2.50% 1.00% 2.50%            
Notice period to cure termination due to breach 60 days                                  
Period of notice for termination of Joint Ownership and exclusive license agreement 60 days                                  
Period of Written notice for termination of Joint Ownership and exclusive license agreement 180 days                                  
Maximum potential payment based on achievement of regulatory milestones                         $ 1,333,000 € 1,025,000        
Right Interest in Joint Intellectual Property 10.00%